LincRNA-p21 Regulates Neointima Formation, Vascular Smooth Muscle Cell Proliferation, Apoptosis, and Atherosclerosis by Enhancing p53 Activity
Atherosclerosis is a major risk factor for cardiovascular disease. The cause of atherosclerosis is not fully understood. However, the proliferation of vascular smooth muscle cells and the formation of neointima are believed to contribute significantly to the development of atherosclerotic lesions. In this study, we identified a long noncoding RNA, lincRNA-p21, as a key regulator of atherosclerosis. We found that the expression of lincRNA-p21 was inhibited in atherosclerotic lesion in both mouse models and human patients. We show in our studies, using cultured cells and mouse models, that loss of lincRNA-p21 accelerates cell proliferation and the formation of atherosclerotic lesion. Conversely, overexpression of lincRNA-p21 inhibits cell proliferation and triggers apoptotic cell death. Thus, lincRNA-p21 could serve as a therapeutic target to treat atherosclerosis and related cardiovascular disorders. See p 1452.
Comparison of Lifestyle-Based and Traditional Cardiovascular Disease Prediction in a Multiethnic

Cohort of Nonsmoking Women
Lifestyle factors, including healthy diet, recreational physical activity, moderate alcohol use, and low adiposity, are an important part of cardiovascular disease (CVD) prevention. However, except for smoking, lifestyle factors have not been included in commonly used risk prediction models. In this case-cohort study of 3279 nonsmoking postmenopausal women sampled from the Women's Health Initiative Observational Study, increasing numbers of healthy lifestyle factors were associated with lower risk of CVD. When lifestyle factors were added to the traditional risk factors from the Pooled Cohort risk score or the Reynolds risk score, only recreational physical activity remained independently associated with CVD risk. The addition of lifestyle factors to traditional factors improved overall model fit but did not result in changes in risk stratification measures. Although lifestyle factors have important effects on CVD risk factors and subsequent risk, their addition to established CVD risk models does not result in clear improvement in clinical prediction. See p 1466.
Roadway Proximity and Risk of Sudden Cardiac Death in Women
Sudden cardiac death (SCD) is a major source of mortality and is the first manifestation of heart disease for the majority of cases. Therefore, modifiable, population-level risk factors for primary prevention are important to identify. Exposure to traffic, measured by residential roadway proximity, is commonly used as a proxy for exposures to air pollution and traffic noise, both of which have been associated with an increased risk of cardiovascular disease, as well as underlying biological mechanisms related to SCD risk. In the present study, we assess the risk of incident SCD, nonfatal myocardial infarction, and fatal coronary heart disease associated with roadway proximity among participants of the Nurses' Health Study, a prospective cohort study. We found that women living closer to large roadways were at an increased risk of SCD and fatal coronary heart disease compared with women living farther away. Although risk elevations are modest, we found that the population-attributable risk for SCD was comparable with that observed for other major SCD risk factors such as smoking, diet, and obesity. These results need to be confirmed in other populations but suggest that exposures to traffic may be an important unidentified risk factor for SCD. See p 1474.
Long-Term Outcomes of Inoperable Patients With Aortic Stenosis Randomly Assigned to Transcatheter Aortic Valve Replacement or Standard Therapy
This article reports 3-year clinical and echocardiographic outcomes of inoperable patients with severe symptomatic aortic stenosis from the only randomized trial of transcatheter aortic valve replacement (TAVR) versus standard therapy (the Placement of Aortic Transcatheter Valves [PARTNER] trial). The results clearly demonstrate significant mortality reduction, reduced hospitalizations, and symptom benefit of TAVR over long-term follow-up. Further, the balloon-expandable bioprosthetic valve was durable over this follow-up period without any indication of structural valve deterioration. However, there was substantial progressive mortality in these elderly patients with aortic stenosis who were undergoing TAVR, mostly owing to Volume 130 ◼ Number 17 ◼ October 21, 2014
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comorbidities. Subgroup analyses demonstrate that the benefit of TAVR was highest in patients with anatomic reasons for inoperability with low Society of Thoracic Surgeons scores (eg, radiation heart disease) and that the mortality benefit was muted in the subgroup of patients with many comorbidities characterized by the highest Society of Thoracic Surgeons scores. The results of this study can inform symptomatic patients with severe aortic stenosis who are deemed inoperable (or an extreme surgical risk) that treatment with this first-generation TAVR procedure will prolong life, improve functional status, and prevent hospitalizations from heart failure and that the valve is durable over at least 3 years follow-up. One of the current clinical challenges is to better identify patients with severe comorbidities in whom TAVR may be considered futile (ie, with no or limited clinical utility). See p 1483.
CD82 Restrains Pathological Angiogenesis by Altering Lipid Raft Clustering and CD44 Trafficking in Endothelial Cells
Angiogenesis is fundamentally important for the pathogenesis and progression of various diseases, including cardiovascular diseases such as myocardial infarction and stroke. Selective, efficient, and persistent perturbation of angiogenesis for the purposes of disease treatment is still beyond our reach. The limited efficacy of the angiogenesis therapy based on vascular endothelial growth factor and fibroblast growth factor antagonism highlights that the mechanism of pathological angiogenesis is unique. In addition to unveiling the inhibitory roles of tetraspanin CD82 in endothelial cell movement and pathological angiogenesis, our study reveals a novel angiogenesis-regulatory mechanism by which membrane glycosphingolipids and their derived lipid rafts in endothelial cells modulate angiogenic potential. Our study also presents CD82ganglioside-CD44 signaling as a potential therapeutic target against angiogenesis. More important, our findings provide a novel strategy to intervene angiogenesis under pathological conditions, that is, the reorganization of membrane microdomains at the endothelial cell surface. Together with earlier observations of tetraspanin CD151, this study of tetraspanin CD82 supports an emerging notion that tetraspanins could be clinically beneficial through upregulation or downregulation of vascular functions such as endothelial cell movement and angiogenesis. See p 1493.
